RxDoctor Payments Data

Sridevi Agasthi, MD

Hospitalist · Marietta, GANPI 1427257104

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Johnson & Johnson at 26.3% of the total. Reporting peaked in 2024 at $1,092 and has fallen 67.3% since, to $357 in 2025. Among hospitalist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,625in general payments, 2019–2025

Across 180 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$952
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$499
  • UCB, Inc.$324
  • Gilead$228
  • Novartis$227
  • Boehringer Ingelheim$193
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,625100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,625 in reported general payments places this provider in the 95th percentile of 812 hospitalist providers in Georgia.

See all hospitalist providers in Georgia

Medicare billing

Part B allowed, 2024
$110,302
Medicare patients
515
Services billed
1,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$22,674
Atorvastatin Calcium26$196
Pantoprazole Sodium32$185
Metoprolol Succinate17$140
Furosemide31$114
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$94
Torsemide13$85
Ciprofloxacin Hcl15$71
Potassium Chloride11$69
Oxycodone Hcl20$66
Spironolactone11$58
Quetiapine Fumarate11$52
Carvedilol11$39
Prednisone19$36
Amlodipine Besylate16$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$22,67436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 812 hospitalist providers in Georgia.

Other hospitalist in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →